Clinical-stage biopharmaceutical company developing novel, first-in-class and best-in-class therapies for aggressive and treatment-resistant cancers
Clinical-stage biopharmaceutical company developing novel, first-in-class and best-in-class therapies for aggressive and treatment-resistant cancers. Its lead programs include a CDK7 inhibitor and a CDK12/13 inhibitor/Cyclin-K degrader, targeting pathways implicated in breast, prostate, ovarian, pancreatic and other cancers.